Abstract: The present invention relates to termite preferred resource compositions and methods. In embodiments, the present invention is directed to termite preferred resource compositions including materials from a Sabal palm tree material (Sabalpalmetto; Family Arecaceae) and a pesticide toxic to one or more species of termites. In additional embodiment's, the present invention is directed to a method of creating a termite assurance program to limit termite damage to a structure including the steps of providing an initial investigation of termite detection, damage, or activity for a structure; placing a termite station comprising a housing, at least one entry point in the housing allowing for ingress and egress of a termite, and materials from a Sabal palm tree contained within the housing in an area proximate the structure, and inspecting the termite station for live termites or evidence of termite activity after it is placed.

Abstract: A method for conversion of an N-terminal glutamine and/or glutamic acid residue of a protein to pyro-glutamic acid within a purification process.

Abstract: The present invention relates to termite preferred resource compositions and methods. In embodiments, the present invention is directed to termite preferred resource compositions including materials from a Sabal palm tree material (Sabalpalmetto; Family Arecaceae) and a pesticide toxic to one or more species of termites. In additional embodiment's, the present invention is directed to a method of creating a termite assurance program to limit termite damage to a structure including the steps of providing an initial investigation of termite detection, damage, or activity for a structure; placing a termite station comprising a housing, at least one entry point in the housing allowing for ingress and egress of a termite, and materials from a Sabal palm tree contained within the housing in an area proximate the structure, and inspecting the termite station for live termites or evidence of termite activity after it is placed.

Abstract: A method for conversion of an N-terminal glutamine and/or glutamic acid residue of a protein to pyro-glutamic acid within a purification process.

Abstract: A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.

Abstract: A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.

Abstract: A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.

Abstract: A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.